Markets finished last year on a high note, with annual gains between 22% on the Dow Jones and 35% on the NASDAQ. But …
After a massive slip up last year, the tide appears to be turning for small cap vaccine maker Novavax (NVAX). In Wednesday’s trading …
After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign …
In a set of interesting reports, Goldman Sachs telecom expert Brett Feldman turns his eye on the American wireless market – and its …
The old adage of ‘buy low, sell high’ is an oft-repeated mantra in investing circles, and it makes sense, too. There are other …
Exact Sciences Corporation’s (EXAS) preliminary quarterly results blew expectations out of the water. Yesterday, the molecular diagnostics company released preliminary results for its …
In a single day, the talk on the Street has zeroed in on one stock, oncology-focused cell therapy company Adaptimmune Therapeutics (ADAP). Following …
Shoppers everywhere like to find the best value; that’s a given. And investors?
Investors are always on the lookout for stocks poised to deliver hefty returns. While it’s true anyone can measure a stock’s potential by …
We are still in the earliest days of the new decade, one sure to bring with it a plethora of changes. Some we …
